Prelude Therapeutics (PRLD) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Zura Bio (ZURA) over the past year, gaining 177.9% versus a loss of 11.3%. Zura Bio is the larger company by market cap ($383.3 million vs $310.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRLD | ZURA |
|---|---|---|
| Share price | $3.89 | $4.00 |
| Market cap | $310.44M | $383.32M |
| 1-day change | +0.26% | -3.15% |
| YTD return | +34.14% | -23.66% |
| 1-year return | +177.86% | -11.31% |
| 5-year return | -76.08% | — |
| EPS (TTM) | $-0.73 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.83 | $7.44 |
| 52-week low | $1.16 | $3.15 |
| Distance from 52-week high | -43.05% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +136.50% | +350.00% |
| Average volume | 477.67K | 1.44M |
| Shares outstanding | 65.08M | 95.83M |
| Employees | 79 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed ZURA by 189.2 percentage points over the past year.
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
PRLD vs ZURA FAQ
Which is bigger, Prelude Therapeutics or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $383.32M compared with $310.44M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, PRLD or ZURA?
PRLD returned +177.86% over the past 12 months, compared with -11.31% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Prelude Therapeutics and Zura Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Prelude Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Zura Bio.